510(k)

K003809: RAPID DRUGS OF ABUSE SINGLE AND MULTIPLE TEST PANELS

FDA 510(k) · Rapid Diagnostics, Inc. · decided Apr 20, 2001

Key facts

510(k) number K003809
Device name RAPID DRUGS OF ABUSE SINGLE AND MULTIPLE TEST PANELS
Applicant Rapid Diagnostics, Inc.
Product code DKZ
Subsequent product codes DIO, DJC, DJG, JXM, LDJ
Date received Dec 8, 2000
Decision date Apr 20, 2001
Decision Substantially equivalent (SESE)
Submission type Traditional
Review panel Clinical Toxicology
Medical specialty Clinical Toxicology

At a glance

  • None MAUDE adverse event reports
  • None Recall events
  • None UDI device identifiers (GUDID)
  • None Predicate devices cited
  • 1–9 Later submissions citing this device
  • 100–999 510(k)s with this product code
  • No 510(k) summary on file
  • No 510(k) statement on file
  • Not listed On the FDA AI-enabled device list

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Reading a 510(k)

Decision
SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
Predicates
Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
Product code
The three-letter code sets the device type, class and regulation, and groups competing clearances.
Summary or statement
Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.

About 510(k) premarket notifications

A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date:

Browse all 510(k) premarket notifications